/SIGY
SIGY Stock - Sigyn Therapeutics, Inc.
Healthcare|BiotechnologyOTC
$1.71+0.00%
+$0.00 (+0.00%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.88
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SIGY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.69 – $1.73
TARGET (TP)$1.97
STOP LOSS$1.57
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.74
52W High$5.00
52W Low$1.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-5,611 | $-8,856 | $-10,454 | $-536.047 | $-11,300 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-2,519,242 | $-2,455,317 | $-2,147,265 | $-2,008,217 | $-916,434 |
| Net Income | $-3,340,212 | $-4,145,936 | $-3,711,931 | $-3,403,691 | $-1,602,746 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.51 | $-3.77 | $-3.97 | $-0.09 | $-0.22 |
Company Overview
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SIGYBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.36
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-0.36 | — | — |
Q3 2025 | Sep 5, 2025 | — | $-0.90 | — | — |
Q2 2025 | May 20, 2025 | — | $-0.42 | — | — |
Q2 2025 | Apr 15, 2025 | — | $-2.51 | — | — |
Q4 2024 | Nov 19, 2024 | — | $-0.94 | — | — |
Q3 2024 | Aug 19, 2024 | — | $-0.70 | — | — |
Q2 2024 | May 14, 2024 | — | $-0.62 | — | — |
Q1 2024 | Feb 20, 2024 | — | $-0.94 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.80 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-0.80 | — | — |
Q2 2023 | May 16, 2023 | — | $-1.20 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.80 | — | — |
Q4 2022 | Nov 15, 2022 | — | $-0.80 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-0.80 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.02 | — | — |
Q1 2022 | Mar 21, 2022 | — | $-0.03 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.80 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.80 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.01 | — | — |
Q2 2021 | Apr 6, 2021 | — | $-0.11 | — | — |
Latest News
Loading news...
Frequently Asked Questions about SIGY
What is SIGY's current stock price?
Sigyn Therapeutics, Inc. (SIGY) is currently trading at $1.71 per share. The stock has moved +0.00% today.
What is the analyst price target for SIGY?
No analyst price targets are currently available for this stock.
What sector is Sigyn Therapeutics, Inc. in?
Sigyn Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is SIGY's market cap?
Sigyn Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does SIGY pay dividends?
No, Sigyn Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARUXF
Acrux Limited
$0.01
Mkt Cap: $0.0B
AXIM
AXIM Biotechnologies, Inc.
$0.02
Mkt Cap: $0.0B
CLABF
Core One Labs Inc.
$0.00
Mkt Cap: $0.0B
HAVLF
HAVN Life Sciences Inc.
$0.00
Mkt Cap: $0.0B
IRME
IR-Med Inc.
$0.04
Mkt Cap: $0.0B
LMLLF
Pharmadrug Inc.
$0.01
Mkt Cap: $0.0B
PKTX
ProtoKinetix, Incorporated
$0.01
Mkt Cap: $0.0B
REPCF
RepliCel Life Sciences Inc.
$0.00
Mkt Cap: $0.0B
TBRIF
Therma Bright Inc.
$0.04
Mkt Cap: $0.0B
ZLDAF
Zelira Therapeutics Limited
$0.23
Mkt Cap: $0.0B
Explore stocks similar to SIGY for comparison